Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.61 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238016 | 0.91 | KMT2A (0.71) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL9320395 | 0.88 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL5240730 | 0.84 | HSPB1 (0.55) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL4687037 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL4237867 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL2992329 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1MAPTCYP3A4 | |
| SCHEMBL27438045 | 0.83 | TLR9 (0.55) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL4238110 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL9321063 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1MAPTPDE7A | |
| SCHEMBL5148186 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1MAPTPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ALDH1A1 4542/4885KMT2A 3436/4885MEN1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.